Dementia breakthrough as scientists discover key deficiency could play crucial role in disease onset

Researchers at Harvard Medical School have identified a potential breakthrough in understanding Alzheimer’s disease after discovering that insufficient lithium levels in the brain may play a crucial role in the condition’s onset.

The comprehensive study, spanning 10 years and published in Nature, demonstrates that lithium naturally exists in brain tissue where it helps preserve normal cellular function across all major cell types.

|

Lithium level measurements could potentially serve as diagnostic indicators

Among approximately 30 metals examined, lithium emerged as the sole element displaying significantly altered concentrations between participant groups, with changes appearing during the initial phases of cognitive decline.

The metal’s depletion in human brains represents one of the earliest indicators of Alzheimer’s progression, while similar reductions in laboratory mice resulted in accelerated memory deterioration.

The investigation revealed that diminished lithium concentrations sometimes resulted from compromised absorption mechanisms and the metal becoming trapped within amyloid plaques, the protein deposits characteristic of Alzheimer’s pathology.

This binding process effectively removes lithium from its protective role in maintaining neurological health.

Scientists demonstrated that lithium orotate, an alternative lithium formulation, successfully circumvents entrapment by amyloid deposits and reverses memory impairment in mouse models.

This compound proves effective at concentrations merely one-thousandth of those employed in conventional psychiatric therapies, matching the brain’s natural lithium levels.

“Lithium turns out to be like other nutrients we get from the environment, such as iron and vitamin C,” explained senior researcher Bruce Yankner.

“It’s the first time anyone’s shown that lithium exists at a natural level that’s biologically meaningful without giving it as a drug.”

While these results require validation through human clinical trials, the dramatically reduced dosage addresses toxicity concerns associated with traditional lithium treatments in elderly patients.

The discovery could revolutionise screening methods for early-stage Alzheimer’s, with lithium level measurements potentially serving as diagnostic indicators.

|

The discovery could revolutionise screening methods for early-stage Alzheimer’s

These findings challenge established theories about the disease, which impacts approximately 400 million individuals globally.

For decades, researchers have focused on brain abnormalities, including amyloid beta accumulations, tau protein tangles, and depletion of the protective REST protein.

Yet these factors have failed to provide a complete explanation for the condition’s development.

The Harvard team’s work introduces lithium deficiency as a previously unrecognised element in Alzheimer’s pathology, potentially opening new avenues for prevention strategies and therapeutic interventions at much earlier disease stages than currently possible.

_{Images are for reference only.Images and contents gathered automatic from google or 3rd party sources.All rights on the images and contents are with their legal original owners.}